Mart-1
Neoplasm Metastasis
National Cancer Institute (NCI)protein_peptidePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
43 Active assets in the Neoplasm Metastasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Ruijin Hospital | Phase 4 | BBB |
Calcium folinate pentahydrate Ruijin Hospital | Phase 4 | BBB |
FLUOROURACILUM Ruijin Hospital | Phase 4 | BBB |
Irinotecan Eli Lilly and Company | Phase 4 | BBB |
(+)-VINCRISTINE Eli Lilly and Company | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Mart-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →